|
1
|
A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer.
|
Clin J Pain
|
2006
|
1.38
|
|
2
|
Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain.
|
J Support Oncol
|
2007
|
1.18
|
|
3
|
Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: A long-term, open-label safety study.
|
Cancer
|
2009
|
1.11
|
|
4
|
Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study.
|
Curr Med Res Opin
|
2007
|
0.94
|
|
5
|
The efficacy and safety of fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain.
|
Anesth Analg
|
2011
|
0.91
|
|
6
|
Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
|
Clin Ther
|
2007
|
0.86
|
|
7
|
Rivastigmine for Alzheimer's Disease: Improvement Versus Reduced Worsening.
|
Prim Care Companion J Clin Psychiatry
|
2000
|
0.85
|
|
8
|
Centrally acting antiemetics mitigate nausea and vomiting in patients with Alzheimer's disease who receive rivastigmine.
|
Clin Neuropharmacol
|
2002
|
0.85
|
|
9
|
Improved pharmacokinetics of sumatriptan with Breath Powered™ nasal delivery of sumatriptan powder.
|
Headache
|
2013
|
0.83
|
|
10
|
Long-term safety and tolerability of fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic pain: an 18-month study.
|
J Pain Symptom Manage
|
2010
|
0.83
|
|
11
|
A randomized, double-blind, placebo-controlled study of breath powered nasal delivery of sumatriptan powder (AVP-825) in the treatment of acute migraine (The TARGET Study).
|
Headache
|
2014
|
0.82
|
|
12
|
A novel 12-week study, with three randomized, double-blind placebo-controlled periods to evaluate fentanyl buccal tablets for the relief of breakthrough pain in opioid-tolerant patients with noncancer-related chronic pain.
|
Pain Med
|
2010
|
0.82
|
|
13
|
Consistent and clinically relevant effects with fentanyl buccal tablet in the treatment of patients receiving maintenance opioid therapy and experiencing cancer-related breakthrough pain.
|
Pain Pract
|
2010
|
0.80
|
|
14
|
Fentanyl buccal tablet for the treatment of breakthrough pain: pharmacokinetics of buccal mucosa delivery and clinical efficacy.
|
Perspect Medicin Chem
|
2010
|
0.78
|
|
15
|
Effect of fentanyl buccal tablet on pain-related anxiety: a 4-week open-label study among opioid-tolerant patients with chronic and breakthrough pain.
|
J Opioid Manag
|
2011
|
0.77
|
|
16
|
Assessment of the relative potency of fentanyl buccal tablet to intravenous morphine in healthy volunteers using a thermally induced hyperalgesia pain model.
|
J Clin Pharmacol
|
2011
|
0.75
|
|
17
|
Clinical pharmacology of fentanyl buccal tablet for the treatment of breakthrough pain.
|
Expert Rev Clin Pharmacol
|
2008
|
0.75
|
|
18
|
Index of Suspicion. Case 1: Status epilepticus, hypertension, and tachycardia in a 5-year-old boy. Case 2: Cardiopulmonary arrest during gymnastics practice in a teenage girl. Case 3: Acute renal failure in a teenage boy who has autism and pica.
|
Pediatr Rev
|
2011
|
0.75
|